IRIS
ROGLIANI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 81.049
AS - Asia 13.562
EU - Europa 9.152
SA - Sud America 1.964
Continente sconosciuto - Info sul continente non disponibili 1.504
AF - Africa 176
OC - Oceania 47
Totale 107.454
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 80.575
SG - Singapore 6.281
CN - Cina 2.458
IT - Italia 1.938
BR - Brasile 1.613
RU - Federazione Russa 1.417
HK - Hong Kong 1.314
VN - Vietnam 1.101
IE - Irlanda 1.053
DE - Germania 885
UA - Ucraina 809
FR - Francia 755
KR - Corea 751
GB - Regno Unito 528
PL - Polonia 524
BD - Bangladesh 458
FI - Finlandia 396
JP - Giappone 372
SE - Svezia 256
CA - Canada 253
NL - Olanda 207
IN - India 172
ID - Indonesia 137
AR - Argentina 114
MX - Messico 94
ES - Italia 79
IQ - Iraq 73
AT - Austria 69
ZA - Sudafrica 58
CO - Colombia 51
PK - Pakistan 49
TR - Turchia 49
EC - Ecuador 46
AU - Australia 42
BE - Belgio 42
MY - Malesia 38
VE - Venezuela 37
CL - Cile 35
UZ - Uzbekistan 33
EG - Egitto 32
TW - Taiwan 32
PH - Filippine 31
PE - Perù 28
SA - Arabia Saudita 27
CR - Costa Rica 24
PT - Portogallo 24
AE - Emirati Arabi Uniti 22
IL - Israele 22
JM - Giamaica 21
RO - Romania 21
GR - Grecia 20
PY - Paraguay 20
MA - Marocco 19
CZ - Repubblica Ceca 18
TH - Thailandia 18
JO - Giordania 17
KE - Kenya 17
LT - Lituania 17
TN - Tunisia 16
AL - Albania 15
NP - Nepal 13
IR - Iran 12
UY - Uruguay 12
A2 - ???statistics.table.value.countryCode.A2??? 11
TT - Trinidad e Tobago 11
DZ - Algeria 10
EU - Europa 10
KZ - Kazakistan 10
NI - Nicaragua 10
PA - Panama 10
BH - Bahrain 9
CH - Svizzera 9
DO - Repubblica Dominicana 9
HN - Honduras 9
SV - El Salvador 9
BG - Bulgaria 8
DK - Danimarca 8
ET - Etiopia 8
KG - Kirghizistan 8
LB - Libano 8
AZ - Azerbaigian 7
HR - Croazia 7
PR - Porto Rico 7
HU - Ungheria 6
KH - Cambogia 6
RS - Serbia 6
AM - Armenia 5
BO - Bolivia 5
GT - Guatemala 5
KW - Kuwait 5
LV - Lettonia 5
NZ - Nuova Zelanda 5
SY - Repubblica araba siriana 5
BA - Bosnia-Erzegovina 4
BS - Bahamas 4
LY - Libia 4
MK - Macedonia 4
OM - Oman 4
SI - Slovenia 4
CI - Costa d'Avorio 3
Totale 105.918
Salva come PNG Salva come JPEG
Città #
Wilmington 19.881
Houston 18.384
Woodbridge 18.105
Fairfield 2.945
Singapore 2.913
Ashburn 2.055
San Jose 1.602
Ann Arbor 1.452
Hong Kong 1.286
Chandler 1.230
Seattle 1.202
Cambridge 955
Dublin 898
Council Bluffs 854
Beijing 782
Medford 685
New York 591
Jacksonville 564
Santa Clara 560
Rome 533
Dearborn 458
Kraków 456
Los Angeles 441
The Dalles 433
Ho Chi Minh City 360
Tokyo 320
Lawrence 318
Zhengzhou 282
Dallas 276
Lauterbourg 274
Hanoi 258
Moscow 227
Buffalo 225
Helsinki 200
San Diego 180
Chicago 178
Boardman 172
São Paulo 166
Milan 151
Monte Vista 137
Menlo Park 106
Colorado Springs 105
London 93
Phoenix 90
Jakarta 85
Naples 85
Shanghai 85
North Bergen 78
Redondo Beach 77
Hangzhou 75
Nuremberg 75
Toronto 71
Orem 68
Brooklyn 65
Norwalk 63
Redwood City 63
Denver 62
Montreal 59
San Francisco 58
Atlanta 57
Warsaw 55
Guangzhou 53
Munich 53
Columbus 52
Stockholm 50
Rio de Janeiro 49
Belo Horizonte 48
Cardiff 46
Palo Alto 46
Frankfurt am Main 45
Salt Lake City 44
Jinan 42
Nanjing 42
Chennai 40
Haiphong 40
Da Nang 39
Hefei 39
Poplar 39
Bar Harbor 38
Brussels 38
Verona 38
Mülheim 37
Dong Ket 35
Lappeenranta 35
Manchester 35
Detroit 32
Boston 31
Brasília 31
Johannesburg 31
Miami 30
Seoul 30
Tampa 30
Turin 29
Amsterdam 28
Falls Church 28
Mountain View 28
Tashkent 28
Mexico City 27
Vienna 27
Baghdad 26
Totale 86.023
Salva come PNG Salva come JPEG
Nome #
Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules 562
β2-Agonist Therapy in Lung Disease 554
An update on the pharmacotherapeutic management of lower respiratory tract infections 531
Vats lung reduction in patients with advanced emphysema 527
Awake thoracoscopic biopsy of interstitial lung disease 524
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 518
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 511
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 509
Interaction between corticosteroids and muscarinic antagonists in human airways 506
A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD 504
Minimalist video-assisted thoracic surgery biopsy of mediastinal tumors 504
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 503
Thoracoscopic reduction pneumoplasty for severe emphysema: Do pleural adhesions affect outcome? 499
Effect of lung volume reduction surgery for severe emphysema on right ventricular function 495
Surgery of giant emphysematous bullae 495
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 492
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 492
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 491
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 488
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 487
Completion lobectomy after bilateral lung volume reduction for emphysema: Salvage option or fancy? 486
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 485
Asthma and comorbid medical illness. 485
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 485
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 484
Airflow obstruction: Is it asthma or is it COPD? 483
Optimizing drug delivery in COPD: The role of inhaler devices 483
Unilateral thoracoscopic reduction pneumoplasty for asymmetric emphysema 480
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 479
Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. 478
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 475
Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement 472
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 472
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 470
Serum- and Glucocorticoid-Inducible Kinase 1 Delay the Onset of Endothelial Senescence by Directly Interacting with Human Telomerase Reverse Transcriptase 469
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 467
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 466
Feasibility and results of awake thoracoscopic resection of solitary pulmonary nodules 463
Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma 463
Completion lobectomy after bilateral lung volume reduction for emphysema: salvage option or fancy? 462
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 462
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 462
Occupational allergy to horse allergens: More than exposure to horses! 461
Clinical features and outcome of hospitalized patients with HSV-1 DNA in the lower respiratory tract 459
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 458
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 455
Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis 455
The role of epsilon PKC in acute and chronic diseases: Possible pharmacological implications of its modulators 454
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 453
Umeclidinium for the treatment of chronic obstructive pulmonary disease 452
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 452
Results of unilateral lung volume reduction surgery in patients with distinct heterogeneity of emphysema between lungs 449
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 449
Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents? 449
Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma? 449
Metabolic syndrome and risk of pulmonary involvement 448
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 448
Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life? 447
Tiotropium formulations and safety: a network meta-analysis 447
Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity 442
Role of muscarinic antagonists in asthma therapy 442
Asthma and comorbid medical illness 441
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 441
Bronchodilator therapy for chronic cough 441
HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema 440
Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review 440
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 439
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis 438
Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298 437
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 437
Analysis of TNF-alpha promoter polymorphisms in the susceptibility to beryllium hypersensitivity 436
How many systemic reactions to skin prick tests could be preventable in defined conditions? 436
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 435
Is allergic sensitization to siberian hamster preventable in high-risk individuals who are already sensitized or exposed to furry animals? 435
Asthma management in a specialist setting: Results of an Italian Respiratory Society survey 435
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD 435
New Treatments for COPD in the Elderly 433
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 433
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 433
The Challenges of Precision Medicine in COPD 433
Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in “real life”? 433
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 433
Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis 432
Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. 431
Brensocatib: Dipeptidyl peptidase 1 (DPP1) inhibitor Treatment of non-cystic fibrosis bronchiectasis 431
The effect of indacaterol during an acute exacerbation of COPD 429
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 429
Dog allergen immunotherapy and allergy to furry animals 428
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 428
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 425
Defining Phenotypes in COPD: An Aid to Personalized Healthcare 425
Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified? 425
The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. 424
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD 424
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 423
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 422
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 421
Translational study searching for synergy between glycopyrronium and indacaterol 421
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 421
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 420
Totale 46.015
Salva come PNG Salva come JPEG
Categoria #
all - tutte 292.720
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 292.720
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.766 0 0 87 73 105 322 422 149 182 301 279 846
2022/20233.538 466 250 122 394 271 903 321 208 316 36 161 90
2023/20241.769 353 46 131 37 128 376 110 200 59 69 31 229
2024/20259.740 297 1.970 989 476 313 424 805 526 885 1.022 1.061 972
2025/202616.318 1.088 931 1.735 1.276 1.618 664 2.081 1.941 2.042 1.141 1.076 725
2026/20272.558 1.483 1.008 67 0 0 0 0 0 0 0 0 0
Totale 107.454